Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,365.09 102.53 0.63%
S&P 500 1,854.10 11.12 0.60%
NASDAQ 4,055.63 21.47 0.53%
Ticker Volume Price Price Delta
STOXX 50 3,128.83 37.31 1.21%
FTSE 100 6,577.50 35.89 0.55%
DAX 9,285.94 112.23 1.22%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

Financial Results, New Drug Applications, and Stock Price Movements - Research Report on Endo, Bristol-Myers Squibb, Express



Financial Results, New Drug Applications, and Stock Price Movements - Research
  Report on Endo, Bristol-Myers Squibb, Express Scripts, AbbVie, and Incyte

PR Newswire

NEW YORK, November 8, 2013

NEW YORK, November 8, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Endo
Health Solutions Inc. (NASDAQ: ENDP), Bristol-Myers Squibb Co. (NYSE: BMY),
Express Scripts Holding Company (NASDAQ: ESRX), AbbVie Inc. (NYSE: ABBV), and
Incyte Corporation (NASDAQ: INCY). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Endo Health Solutions Inc. Research Report

On November 5, 2013, Endo Health Solutions Inc. (Endo) reported its Q3 2013
financial results. The Company's revenues declined 4.7% YoY to c.$715.0
million during the quarter. Net income attributable to Endo was $40.2 million
or $0.33 per diluted share in Q3 2013, compared to $53.8 million or $0.45 per
diluted share in Q3 2012. Commenting on the results, Rajiv De Silva, President
and CEO of Endo, said, "Endo continues to evolve through what is an important
transition period for the company. During the third quarter we have carried
the momentum we established in June with the announcement of our new strategic
direction. We have implemented a leaner operating model, announced progress in
our branded pipeline, announced the acquisition of Boca Pharmacal and
continued to assemble a strong leadership team to lead Endo towards our
objective of creating a leading specialty healthcare company." The Full
Research Report on Endo Health Solutions Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

[http://www.analystscorner.com/r/full_research_report/059c_ENDP]

--

Bristol-Myers Squibb Co. Research Report

On November 2, 2013, Bristol-Myers Squibb Co. (Bristol-Myers Squibb) announced
the submission of a New Drug Application (NDA) to Japan's Pharmaceutical and
Medical Devices Agency seeking the world's first interferon-free and
ribavirin-free treatment regimen for patients with chronic hepatitis C.
According to the Company, the submission was based on results from a Phase III
study demonstrating that the 24-week, all-oral, interferon-free and
ribavirin-free regimen of daclatasvir (DCV) and asunaprevir (ASV) achieved an
overall sustained virologic response 24 weeks after the end of treatment
(SVR[24]) of 84.7% in Japanese patients with chronic hepatitis C (HCV)
genotype 1b who were either interferon-ineligible/intolerant (87.4% SVR[24])
or non-responders (null and partial) to interferon-based therapies (80.5%
SVR[24]). Brian Daniels, M.D., Senior Vice President of Global Development and
Medical Affairs, Research and Development at Bristol-Myers Squibb, said, "With
our submission in Japan, we are pleased to be one step closer to bringing a
potential new treatment option to the many people living with HCV in that
country." The Full Research Report on Bristol-Myers Squibb Co. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.analystscorner.com/r/full_research_report/81a9_BMY]

--

Express Scripts Holding Company Research Report

On November 4, 2013, Express Scripts Holding Company (Express Scripts)
announced that the Company will present at the Credit Suisse Healthcare
Conference on November 12, 2013 at 9:00 a.m. MST (11:00 a.m. EST) at the
Phoenician Hotel in Scottsdale, Arizona. The Company added that its
presentation will be broadcast via the Internet and can be accessed on the
Investor Relations section of the Express Scripts website. The webcast will be
archived and available for replay for 14 days. The Full Research Report on
Express Scripts Holding Company - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/91a7_ESRX]

--

AbbVie Inc. Research Report

On November 5, 2013, AbbVie Inc's stock declined 1.21%, ending the day at
$48.17. Over the previous three trading sessions, shares of AbbVie declined
0.58% compared to the S&P 500 which gained 0.37% during the same period. The
Full Research Report on AbbVie Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

[http://www.analystscorner.com/r/full_research_report/273c_ABBV]

--

Incyte Corporation Research Report

On October 31, 2013, Incyte Corporation (Incyte) reported its Q3 2013
financial results. The Company's total revenues increased 40.7% YoY to $85.1
million during the quarter. Net loss was $22.0 million or $0.14 per diluted
share in Q3 2013, compared to net loss of $21.7 million or $0.17 per diluted
share in Q3 2012. Commenting on the results, Paul A. Friedman, M.D., Incyte's
President and CEO, said, "The growth of Jakafi remains strong, and we're
encouraged by the sustained steady rate of new prescriptions for patients with
myelofibrosis and continued evidence that physicians are successfully
individualizing dosing. With potential approval of ruxolitinib for use in
polycythemia vera in late 2014 and recent data from the RECAP trial that
suggest potential benefit in pancreatic cancer and opportunities in other
solid tumors, we see several drivers to further grow revenues for our first
product, while we continue to deliver promising results for other compounds in
our growing pipeline." The Full Research Report on Incyte Corporation -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/076e_INCY]

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://AnalystsCorner.com

 

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement